Susquehanna Fundamental Investments, LLC Cel Sci Corp Transaction History

Susquehanna Fundamental Investments, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$3.93 - $7.7 $100,608 - $197,120	-25,600 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$7.1 - $12.82 $26,980 - $48,716	3,800 Added 17.43%	25,600 $182,000
Q3 2021 Nov 15, 2021	BUY	$7.64 - $12.49 $166,552 - $272,282	21,800 New	21,800 $240,000
Q2 2021 Aug 11, 2021	SELL	$8.68 - $27.49 $94,612 - $299,641	-10,900 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$12.0 - $27.64 $130,800 - $301,276	10,900 New	10,900 $166,000
Q4 2020 Feb 16, 2021	SELL	$11.05 - $16.62 $364,650 - $548,460	-33,000 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$11.69 - $14.54 $9,352 - $11,632	-800 Reduced 2.37%	33,000 $421,000
Q2 2020 Aug 14, 2020	BUY	$9.75 - $17.6 $329,550 - $594,880	33,800 New	33,800 $504,000

6.16M

16.6K

148K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $46M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Susquehanna Fundamental Investments, LLC, based on Form 13F filings with the SEC.

Stay updated on Susquehanna Fundamental Investments, LLC with notifications on news.